Altimmune, Inc. — Director's Dealing 2022

Jun 22, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2022-06-20

Reporting Person: Schafer Klaus (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-06-20	Common Stock, par value $0.0001	M	60	$2.4	Acquired	8960	Direct
2022-06-20	Common Stock, par value $0.0001	M	159	$2.4	Acquired	9119	Direct
2022-06-20	Common Stock, par value $0.0001	M	60	$2.4	Acquired	9179	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-20	Stock Options (option to buy)	$2.4	M	60	Disposed	2022-12-30	Common Stock, par value $0.0001 (60)	Direct
2022-06-20	Stock Options (option to buy)	$2.4	M	159	Disposed	2022-07-04	Common Stock, par value $0.0001 (159)	Direct
2022-06-20	Stock Options (option to buy)	$2.4	M	60	Disposed	2022-07-04	Common Stock, par value $0.0001 (60)	Direct

Footnotes

F1: This option was previously reported as covering 1,791 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018.

F2: This option was previously reported as covering 4,775 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018.

F3: This option is fully vested and exercisable as of the date hereof.